Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in  engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.



After working for 10 years in Paris at Gustave Roussy institute, Sanofi-Aventis, INSERM Unit 535 and Necker Hospital, he passed in 2009 the national health and medical research institute (INSERM) competitive examination for a research engineer permanent contract.  

Then, he worked in an epidemiology unit at the Cardiovascular Research Center of Paris (PARCC) located in Georges Pompidou European hospital. In 2013, he decided to join the  Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon with his engineer permanent contract. He teaches statistics, data Analysis and methodology in master’s degree and in medical school. 

Research thematic:

Development and improvement of prognostic and/or predictive tools at population and individual level. 

Main areas of expertise:  

- Statistics and epidemiology

- Clinical trial design ans analysis

- Clinical research

- Genetic epidemiology (linkage and association analyses)

- Oncology

- Solid transplantation (kidney and heart)

- Cardiology

Main ongoing external collaborations :

- GERCOR (Multidisciplinary Group in Oncology)

- Fondation ARCAD (Aide et Recherche en Cancérologie Digestive)

- AGEO (Association des Gastro-Entérologues Oncologues)

- FRENCH (Fédération de Recherche EN Chirurgie)

Tools online

- Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score 

- Prognostic Nomogram and Score to Predict Overall Survival in Second Line Chemotherapy for Advanced Pancreatic Cancer: The PROSCAP score 

Principaux articles

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

sample

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : New England Journal of Medicine

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

sample

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Derniers articles

sample

BACKGROUND:Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Exp Hematol Oncol

sample

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ

sample

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology

sample

AbstractTemozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)....

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Endocrine-Related Cancer

sample

BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Nom de la revue : Ann Oncol

sample

AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, ,
Nom de la revue : Expert Review of Anticancer Therapy

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurelia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

sample

AbstractThe diagnosis system for allograft loss lacks accurate individual risk stratification on the basis of...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : J Am Soc Nephrol

sample

ABSTRACT Rationale:The role of circulating antibodies in addition to traditional cardiovascular risk factors in...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Test

sample

AbstractBackground The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Dernières actualités

Derniers outils

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : Dr. Amélie ANOTA, Dr. Dewi VERNEREY, Dr. Amélie ANOTA, Pr. Franck BONNETAIN, Dr. Amélie ANOTA

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Currently, the management of advanced pancreatic cancer patients is complex in second-line palliative chemotherapy...

Posté par : Dr. Dewi VERNEREY, Dr. Angélique VIENOT

2015-2018 © Copyright - UMQVC.org

Website by Pearlweb